Pharnext SA (PNEXF PINK) stock market data APIs
$999999.9999
0(0%)
as of December 9, 2024
Pharnext SA Financial Data Overview
Price chart is built with
Anychart
Pharnext S.C.A., a clinical-stage biopharmaceutical company, engages in developing novel therapies for neurodegenerative diseases. Its products in clinical development include PXT3003, a synergistic combination of baclofen, naltrexone, and sorbitol formulated as an oral solution for the treatment of charcot-marie-tooth disease type 1A; and PXT864, a novel fixed-dose synergistic combination of baclofen and acamprosate formulated as a pill for neurodegenerative diseases. The company was incorporated in 2007 and is headquartered in Suresnes, France.
Prev. Close
999999.9999
Open
999999.9999
Volume
0
High
999999.9999
Low
999999.9999
52 wk Range
999999.9999-999999.9999
Market Cap
413 K
P/E Ratio
0
Shares Outstanding
3 989 M
Revenue
172 K
EPS
-0.3545
Beta
-313.293
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Pharnext SA data using free add-ons & libraries
Get Pharnext SA Fundamental Data
Pharnext SA Fundamental data includes:
- Net Revenue: 172 K
- EBITDA: -23 308 604
- Earnings Per Share: -999 999
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2020-10-15
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pharnext SA News
New
Pharnext Holds Shareholders Meeting and Appoints Dr. James Kuo to Renewed Board of Directors
Pharnext shareholders approve 2021 financial statements and key resolutions at Annual General Meeting Dr. James Kuo co-optation to the Board brings key strategic experience to Pharnext PARIS, FRANCE ...
Pharnext: Shareholder Letter
PARIS, FRANCE / ACCESSWIRE / June 21, 2021 / Pharnext SA (FR0011191287 - ALPHA), an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combi...
Pharnext: Shareholder Letter
PARIS, FRANCE / ACCESSWIRE / June 21, 2021 / Pharnext SA (FR0011191287 - ALPHA), an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combi...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- 100 000+ API requests per day
- EOD Data - All World Extended
- Splits and Dividends
- Fundamental Data
- Bonds Data
- Options Data
- 1000+ currency pairs
- 1000+ cryptocurrency pairs
